GUFIC BIOSCIENCES LTD.

Gufic Biosciences Ltd has received a rejection from NSE for its waiver application regarding a penalty of ₹1,72,000 (excluding GST) imposed for non-compliance with SEBI LODR Regulations, 2015. The penalty relates to the appointment of an additional director who had crossed the age of seventy-five without shareholder approval via special resolution. The company had previously paid a ₹8,000 penalty to BSE for a similar issue in the June 2024 quarter. Gufic Biosciences will now pay the NSE penalty by October 3, 2026, as stipulated.

Gufic Biosciences Ltd has announced the promotion and change in designation of two senior management personnel, effective September 02, 2026. Ms. Ami Shah has been promoted to Head-Legal, while continuing her roles as Company Secretary & Compliance Officer. Mr. Pinak Padhya has been promoted to President – Sales & Marketing. These changes were approved by the Board of Directors based on the recommendation of the Nomination & Remuneration Committee.

Gufic Biosciences Ltd announced its Board of Directors has approved the incorporation of a subsidiary in the Philippines. The company will invest up to USD 250,000 to subscribe to the equity share capital, aiming to hold approximately 99.99% of the subsidiary. The new entity, tentatively named Gufic Philippines Inc., will focus on marketing, sales, and distribution of Gufic's pharmaceutical products in the Philippines, facilitating business expansion and IP management in the region. The incorporation is subject to statutory and regulatory approvals.

Gufic Biosciences Ltd announced its unaudited financial results for the quarter ended June 30, 2026, on August 14, 2026. The Board of Directors also approved the incorporation of a subsidiary in the Philippines. The results were presented on both standalone and consolidated bases, with a limited review report attached. The company's primary business segment remains Pharmaceuticals.

Gufic Biosciences Ltd announced that its Board of Directors, in a meeting held on August 14, 2026, approved the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The results were presented on both standalone and consolidated bases, along with the limited review report. Additionally, the Board approved the incorporation of a subsidiary in the Philippines and an investment in its equity share capital, subject to regulatory approvals. The meeting commenced at 5:00 p.m. and concluded at 6:10 p.m.

Gufic Biosciences Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's commitment to responsible business practices, governance, and sustainable value creation. It covers environmental stewardship, employee well-being, ethical conduct, and community development initiatives. The company operates primarily in pharmaceutical manufacturing and marketing, with 100% of its turnover from this sector. Exports contributed 23.07% to the total turnover for FY26. Gufic Biosciences has 31 national locations (3 plants, 28 offices) and 3 international offices.

Gufic Biosciences Ltd has announced its 42nd Annual General Meeting (AGM) will be held on Friday, September 4, 2026, at 3:30 PM IST via Video Conference/Other Audio Visual Means (VC/OAVM). The company is submitting its Annual Report for the Financial Year 2025-26, which includes the Business Responsibility and Sustainability Report, along with the Notice of the AGM. The report and notice are being sent electronically to registered members and uploaded on the company's website. Shareholders without registered email IDs will receive a letter with a web link to access the Annual Report.

Gufic Biosciences Ltd has announced its 42nd Annual General Meeting (AGM) will be held on Friday, September 4, 2026, at 3:30 p.m. IST via Video Conferencing. The meeting will address ordinary and special businesses, including the adoption of financial statements for FY26, declaration of a final dividend of 10% (₹0.10 per share), appointment of a director, ratification of cost auditor remuneration, and re-appointment of a whole-time director. The company's Register of Members and Share Transfer Books will be closed from August 29 to September 4, 2026, for the AGM and dividend payment.

Gufic Biosciences Ltd has announced the schedule for its 42nd Annual General Meeting (AGM), set to take place on Friday, September 04, 2026, at 3:30 p.m. IST via Video Conferencing. The company has also fixed Friday, August 28, 2026, as the record date for determining eligibility for the payment of a final dividend for the financial year ended March 31, 2026, subject to shareholder approval. The Register of Members and Share Transfer Books will be closed from Saturday, August 29, 2026, to Friday, September 04, 2026, inclusive, for the AGM and dividend payment. The AGM agenda includes adopting financial statements, declaring a 10% final dividend (₹0.10 per share), appointing a director, and ratifying cost auditor remuneration.

Gufic Biosciences Ltd has announced that its Board of Directors will convene on August 14, 2026. The primary agenda item is the consideration and approval of the company's Unaudited Financial Results for the quarter ended June 30, 2026. These results will be presented on both a standalone and consolidated basis. Additionally, the company confirmed that the trading window for its equity shares will remain closed until 48 hours after the declaration of these financial results, in line with SEBI regulations and the company's insider trading code.